
    efficacy did not meet the continuance criteria and dmc recommended to stop enrollment.
  
['bladder cancer', 'urothelial carcinoma', 'metastatic urothelial carcinoma', 'renal pelvis carcinoma', 'ureter carcinoma', 'urinary bladder carcinoma', 'urethra carcinoma', 'muscle invasive bladder cancer']
['rucaparib']

        Inclusion Criteria:

          -  Have histologically or cytologically confirmed locally advanced unresectable or
             metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter,
             urinary bladder or urethra)

          -  Received 1 or 2 prior treatment regimens for advanced or metastatic disease

          -  Confirmed radiologic disease progression during or following recent treatment

          -  Mandatory biopsy is required during screening

          -  Measurable disease per RECIST v1.1

          -  Adequate organ function

          -  ECOG 0 or 1

        Exclusion Criteria:

          -  Prior treatment with a PARP inhibitor

          -  Symptomatic and/or untreated CNS metastases

          -  Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption
             of rucaparib
      